簡易檢索 / 詳目顯示

回結果列表
研究生： 郭凡綺
Kuo, Fan-Chi
論文名稱： 於台灣第二型糖尿病病人探討新型降血糖藥品與非酒精性脂肪肝病之關係性
Association between use of new glucose-lowering agents and nonalcoholic fatty liver disease among patients with type 2 diabetes in Taiwan
指導教授： 歐凰姿
Ou, Huang-Tz
共同指導教授: 吳玉琴
Wu, Yu-Chin
學位類別： 碩士
Master
系所名稱： 醫學院 - 臨床藥學與藥物科技研究所
Institute of Clinical Pharmacy and Pharmaceutical sciences
論文出版年： 2022
畢業學年度： 110
語文別： 中文
論文頁數： 147
中文關鍵詞： 第二型糖尿病 、非酒精性脂肪肝病 、非酒精性脂肪肝炎 、雙基胜肽酶-4抑制劑 、類升糖素胜肽-1受體促效劑 、第二型鈉-葡萄糖轉運蛋白抑制劑
外文關鍵詞： type 2 diabetes, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors
相關次數： 點閱：75  下載：0 
分享至:
查詢本校圖書館目錄 查詢臺灣博碩士論文知識加值系統 勘誤回報
    • 中文摘要 I EXTENDED ABSTRACT III 表目錄 XII 圖目錄 XIV 第一篇 於台灣第二型糖尿病病人探討新型降血糖藥品與非酒精性脂肪肝病之關係性 1 第一章 研究背景 1 第二章 文獻回顧 2 第一節 肝臟疾病與糖尿病關聯之介紹 2 2.1.1 肝臟疾病定義與臨床症狀 2 2.1.2 肝臟疾病之進展 4 2.1.3 非酒精性脂肪肝病之流行病學 5 2.1.4 非酒精性脂肪肝病之機轉 6 2.1.5 非酒精性脂肪肝病之危險因子 8 2.1.6 非酒精性脂肪性肝病之相關併發症 9 2.1.7 非酒精性脂肪性肝病之治療 10 第二節 新型降血糖藥品於肝臟疾病之關聯 12 2.2.1 DPP-4 inhibitors 12 2.2.2 GLP-1 receptor agonists 15 2.2.3 SGLT-2 inhibitors 19 第三節 總結降血糖藥品於肝臟疾病之機轉與效果 22 第四節 降血糖藥品之肝臟疾病觀察性研究 24 第五節 新型降血糖藥品之肝臟疾病持續進行之臨床試驗 27 第三章 研究目的 28 第一節 文獻回顧總結 28 3.1.1 新型降血糖藥品與非酒精性脂肪肝病相關之臨床試驗 28 3.1.2 新型降血糖藥品與非酒精性脂肪肝病相關之觀察性研究 30 第二節 論文研究目的 31 第三節 論文研究假設 31 第四章 研究方法 31 第一節 研究架構 31 4.1.1 研究類型 31 4.1.2 研究材料 31 第二節 新型降血糖藥品與肝臟疾病關係性之分析 32 4.2.1 研究設計 32 4.2.2 研究世代納入條件 32 4.2.3 研究世代排除條件 32 4.2.4 觀察結果 32 4.2.5 研究對象配對流程 32 4.2.6 研究藥品 33 4.2.7 結果分析 34 4.2.8 研究流程 38 第三節 研究名詞與操作型定義 39 第四節 統計分析 53 4.4.1 統計工具 53 4.4.2 資料分析方法 53 第五章 研究結果 56 第一節 研究對象之篩選流程結果 56 第二節 第二型糖尿病病人的非酒精性脂肪性肝病之發生情況 58 第三節 研究對象之基本特徵 59 第四節 研究藥品與非酒精性脂肪性肝病之關係性分析 66 5.4.1 主要分析 (primary analyses) 66 5.4.2 次要分析 (secondary analyses) 68 5.4.3 次族群分析 (subgroup analyses) 81 5.4.4 敏感性分析 (sensitivity analyses) 86 第六章 研究討論 91 第一節 研究族群臨床特質與非酒精性脂肪肝病發生之討論 91 第二節 新型降血糖藥品與非酒精性之脂肪肝病分析結果之討論 92 6.2.1 DPP-4 inhibitors之分析結果 92 6.2.2 GLP-1 RAs之分析結果 96 6.2.3 SGLT-2 inhibitors之分析結果 102 6.2.4 Weight-loss effect之分析結果 107 第七章 研究優勢與限制 108 第一節 研究優勢 108 第二節 研究限制 109 第八章 結論及建議 119 第九章 未來研究方向 120 第二篇 臨床藥事服務—一般病房用藥整合系統之效益分析 122 第一章 簡介 122 第二章 研究動機 125 第三章 分析內容 125 第四章 分析結果 125 第五章 討論與建議 127 參考資料 129 附錄 138

    1. Stefan, N. and K. Cusi, A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol, 2022. 10(4): p. 284-296.
    2. Ekstedt, M., et al., Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology, 2015. 61(5): p. 1547-54.
    3. Paik, J.M., et al., Mortality related to nonalcoholic fatty liver disease is increasing in the United States. Hepatol Commun, 2019. 3(11): p. 1459-1471.
    4. Targher, G., et al., Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol, 2016. 65(3): p. 589-600.
    5. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol, 2020. 5(3): p. 245-266.
    6. Lin, L., et al., The burden and trends of primary liver cancer caused by specific etiologies from 1990 to 2017 at the global, regional, national, age, and sex level results from the Global Burden of Disease Study 2017. Liver Cancer, 2020. 9(5): p. 563-582.
    7. Chen, D.S., Hepatocellular carcinoma in Taiwan. Hepatol Res, 2007. 37 Suppl 2: p. S101-5.
    8. Chalasani, N., et al., The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018. 67(1): p. 328-357.
    9. Zannad, F., et al., Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet, 2015. 385(9982): p. 2067-76.
    10. Rosenstock, J., et al., Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial. Jama, 2019. 321(1): p. 69-79.
    11. Green, J.B., et al., Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2015. 373(3): p. 232-42.
    12. McMurray, J.J.V., et al., Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: A randomized placebo-controlled trial. JACC Heart Fail, 2018. 6(1): p. 8-17.
    13. Marso, S.P., et al., Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2016. 375(4): p. 311-22.
    14. Marso, S.P., et al., Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med, 2016. 375(19): p. 1834-1844.
    15. Gerstein, H.C., et al., Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, 2019. 394(10193): p. 121-130.
    16. Zinman, B., et al., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 2015. 373(22): p. 2117-28.
    17. Neal, B., et al., Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med, 2017. 377(7): p. 644-657.
    18. Wiviott, S.D., et al., Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2019. 380(4): p. 347-357.
    19. Yang, J.Y., et al., Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes. J Diabetes Complications, 2020. 34(11): p. 107706.
    20. Pradhan, R., et al., Glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors and risk of nonalcoholic fatty liver disease among patients with type 2 diabetes. Diabetes Care, 2022. 45(4): p. 819-829.
    21. van Dalem, J., et al., Thiazolidinediones and glucagon-like peptide-1 receptor agonists and the risk of nonalcoholic fatty liver disease: A cohort study. Hepatology, 2021. 74(5): p. 2467-2477.
    22. Newsome, P.N., et al., A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med, 2021. 384(12): p. 1113-1124.
    23. Armstrong, M.J., et al., Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet, 2016. 387(10019): p. 679-690.
    24. Sheka, A.C., et al., Nonalcoholic steatohepatitis: A review. Jama, 2020. 323(12): p. 1175-1183.
    25. Kleiner, D.E., et al., Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005. 41(6): p. 1313-21.
    26. Lee, T.Y., et al., The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease. Int J Cancer, 2017. 141(7): p. 1307-1314.
    27. Kim, H., et al., Metabolic spectrum of liver failure in type 2 diabetes and obesity: From NAFLD to NASH to HCC. Int J Mol Sci, 2021. 22(9).
    28. Simeone, J.C., et al., Clinical course of nonalcoholic fatty liver disease: An assessment of severity, progression, and outcomes. Clin Epidemiol, 2017. 9: p. 679-688.
    29. Younossi, Z.M., et al., Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016. 64(1): p. 73-84.
    30. Huang, J.F., et al., Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis. J Formos Med Assoc, 2020. 119(1 Pt 1): p. 89-96.
    31. Tomah, S., N. Alkhouri, and O. Hamdy, Nonalcoholic fatty liver disease and type 2 diabetes: Where do diabetologists stand? Clin Diabetes Endocrinol, 2020. 6: p. 9.
    32. Paik, J.M., et al., Changes in the global burden of chronic liver diseases from 2012 to 2017: The growing impact of NAFLD. Hepatology, 2020. 72(5): p. 1605-1616.
    33. Estes, C., et al., Modelling NAFLD disease burden in four Asian regions-2019-2030. Aliment Pharmacol Ther, 2020. 51(8): p. 801-811.
    34. Khan, R.S., et al., Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology, 2019. 70(2): p. 711-724.
    35. Lonardo, A., et al., Sex Differences in nonalcoholic fatty liver disease: State of the art and identification of research gaps. Hepatology, 2019. 70(4): p. 1457-1469.
    36. Deurenberg, P., M. Deurenberg-Yap, and S. Guricci, Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev, 2002. 3(3): p. 141-6.
    37. Nishioji, K., et al., Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012. J Gastroenterol, 2015. 50(1): p. 95-108.
    38. Wei, J.L., et al., Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: A population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol, 2015. 110(9): p. 1306-14; quiz 1315.
    39. Mohanty, S.R., et al., Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol, 2009. 50(4): p. 797-804.
    40. Petersen, K.F., et al., Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med, 2010. 362(12): p. 1082-9.
    41. Kuo, C.F., et al., Gout and risk of non-alcoholic fatty liver disease. Scand J Rheumatol, 2010. 39(6): p. 466-71.
    42. Mantovani, A., et al., Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism, 2020. 111s: p. 154170.
    43. Nass, K.J., et al., High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: The lifelines cohort study. Metabolism, 2017. 72: p. 37-46.
    44. Musso, G., et al., Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of randomised trials. Diabetologia, 2012. 55(4): p. 885-904.
    45. Vilar-Gomez, E., et al., Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology, 2015. 149(2): p. 367-78.e5; quiz e14-5.
    46. Aminian, A., et al., Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. Jama, 2021. 326(20): p. 2031-2042.
    47. Cusi, K., et al., Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. Ann Intern Med, 2016. 165(5): p. 305-15.
    48. Belfort, R., et al., A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med, 2006. 355(22): p. 2297-307.
    49. Bril, F., et al., Role of vitamin e for nonalcoholic steatohepatitis in patients with type 2 diabetes: A randomized controlled trial. Diabetes Care, 2019. 42(8): p. 1481-1488.
    50. Musso, G., et al., Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: A meta-analysis. JAMA Intern Med, 2017. 177(5): p. 633-640.
    51. Cariou, B., B. Charbonnel, and B. Staels, Thiazolidinediones and PPARγ agonists: Time for a reassessment. Trends Endocrinol Metab, 2012. 23(5): p. 205-15.
    52. Ko, K.D., K.K. Kim, and K.R. Lee, Does weight gain associated with thiazolidinedione use negatively affect cardiometabolic health? J Obes Metab Syndr, 2017. 26(2): p. 102-106.
    53. Ahrén, B. and J.E. Foley, Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: Focus on alpha and beta cell function and lipid metabolism. Diabetologia, 2016. 59(5): p. 907-17.
    54. Wang, X., et al., Dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin alleviates liver inflammation of diabetic mice by acting as a ROS scavenger and inhibiting the NFκB pathway. Cell Death Discov, 2021. 7(1): p. 236.
    55. Chen, L., et al., Effect of saxagliptin, a dipeptidyl peptidase 4 inhibitor, on non-alcoholic fatty liver disease. Diabetes Metab Syndr Obes, 2020. 13: p. 3507-3518.
    56. Zhuge, F., et al., DPP-4 inhibition by linagliptin attenuates obesity-related inflammation and insulin resistance by regulating M1/M2 macrophage polarization. Diabetes, 2016. 65(10): p. 2966-79.
    57. 衛生福利部中央健康保險署. 健保用藥品項查詢. Available from: https://www.nhi.gov.tw/QueryN/Query1.aspx.
    58. Methodology, W.C.C.f.D.S. ATC/DDD Index. [cited 2021; Available from: https://www.whocc.no/atc_ddd_index/.
    59. UpToDate. [cited 2022 05]; Available from: https://www.uptodate.com/contents/search.
    60. Gastaldelli, A. and G. Marchesini, Time for glucagon like peptide-1 receptor agonists treatment for patients with NAFLD? J Hepatol, 2016. 64(2): p. 262-264.
    61. Bifari, F., et al., Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Pharmacol Res, 2018. 137: p. 219-229.
    62. Wang, X.C., et al., Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. World J Gastroenterol, 2014. 20(40): p. 14821-30.
    63. Wallenius, K., et al., The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic β-oxidation, and induces ketosis. J Lipid Res, 2022. 63(3): p. 100176.
    64. Ferrannini, E., et al., Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes, 2016. 65(5): p. 1190-5.
    65. Xu, L., et al., SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine, 2017. 20: p. 137-149.
    66. Fisher, F.M., et al., FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev, 2012. 26(3): p. 271-81.
    67. Xu, L. and T. Ota, Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization. Adipocyte, 2018. 7(2): p. 121-128.
    68. Mantovani, A., C.D. Byrne, and G. Targher, Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol Hepatol, 2022. 7(4): p. 367-378.
    69. Shen, X., et al., Fetuin a promotes lipotoxicity in β cells through the TLR4 signaling pathway and the role of pioglitazone in anti-lipotoxicity. Mol Cell Endocrinol, 2015. 412: p. 1-11.
    70. Beysen, C., et al., A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes. J Lipid Res, 2008. 49(12): p. 2657-63.
    71. Santos, F.O., et al., Anti-steatotic linagliptin pleiotropic effects encompasses suppression of de novo lipogenesis and ER stress in high-fat-fed mice. Mol Cell Endocrinol, 2020. 509: p. 110804.
    72. Boschmann, M., et al., Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab, 2009. 94(3): p. 846-52.
    73. Jung, C.H. and J.O. Mok, The effects of hypoglycemic agents on non-alcoholic fatty liver disease: Focused on sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. J Obes Metab Syndr, 2019. 28(1): p. 18-29.
    74. Kumar, J., et al., Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map. Dig Liver Dis, 2021. 53(1): p. 44-51.
    75. Kanazawa, I., K. Tanaka, and T. Sugimoto, DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus. Med Sci Monit, 2014. 20: p. 1662-7.
    76. Yilmaz, Y., et al., Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg, 2012. 75(2): p. 240-4.
    77. Joy, T.R., et al., Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World J Gastroenterol, 2017. 23(1): p. 141-150.
    78. Lai, L.L., et al., Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus. Dig Dis Sci, 2020. 65(2): p. 623-631.
    79. Alam, S., et al., Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: A 1-year randomized control trial. Hepat Med, 2018. 10: p. 23-31.
    80. Yen, F.S., et al., Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes. Liver Int, 2020. 40(5): p. 1089-1097.
    81. U.S., N. ClinicalTrials.gov. [cited 2022 05]; Available from: https://clinicaltrials.gov/ct2/search/advanced?cond=&term=&cntry=&state=&city=&dist=.
    82. Dougherty, J.A., E. Guirguis, and K.A. Thornby, A systematic review of newer antidiabetic agents in the treatment of nonalcoholic fatty liver disease. Ann Pharmacother, 2021. 55(1): p. 65-79.
    83. Zhang, Y., et al., Effects and safety of sitagliptin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Horm Metab Res, 2020. 52(7): p. 517-526.
    84. Akaslan, S.B., et al., Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats. Metab Syndr Relat Disord, 2013. 11(4): p. 243-50.
    85. Williams, K.H., et al., Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study. J Diabetes, 2015. 7(6): p. 809-19.
    86. Aroor, A.R., et al., Dipeptidyl peptidase-4 inhibition ameliorates Western diet-induced hepatic steatosis and insulin resistance through hepatic lipid remodeling and modulation of hepatic mitochondrial function. Diabetes, 2015. 64(6): p. 1988-2001.
    87. Yang, Y., et al., Saxagliptin regulates M1/M2 macrophage polarization via CaMKKβ/AMPK pathway to attenuate NAFLD. Biochem Biophys Res Commun, 2018. 503(3): p. 1618-1624.
    88. Ren, J., et al., Sitagliptin is more effective than gliclazide in preventing  pro-fibrotic and pro-inflammatory changes in a rodent model of diet-induced non-alcoholic fatty liver disease. Molecules, 2022. 27(3).
    89. Song, T., et al., Effects of liraglutide on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Ther, 2021. 12(6): p. 1735-1749.
    90. Tang, W., et al., Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. Diabetes Metab Res Rev, 2016. 32(2): p. 200-16.
    91. Nowrouzi-Sohrabi, P., et al., The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. Eur J Pharmacol, 2021. 893: p. 173823.
    92. Astrup, A., et al., Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet, 2009. 374(9701): p. 1606-16.
    93. Mantovani, A., et al., Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Metabolites, 2020. 11(1).
    94. 衛生福利部中央健康保險署. 2014年版_ICD-9-CM2001年版與ICD-10-CM/PCS對應檔. [cited 2021; Available from: https://www.nhi.gov.tw/Content_List.aspx?n=C1C92AB9ED30A9FD&topn=23C660CAACAA159D.
    95. 衛生福利部中央健康保險署. 醫療服務給付項目及支付標準. [cited 2021; Available from: https://www.nhi.gov.tw/query/query2.aspx.
    96. Glasheen, W.P., A. Renda, and Y. Dong, Diabetes Complications Severity Index (DCSI)-Update and ICD-10 translation. J Diabetes Complications, 2017. 31(6): p. 1007-1013.
    97. Glasheen, W.P., et al., Charlson comorbidity index: ICD-9 Update and ICD-10 translation. Am Health Drug Benefits, 2019. 12(4): p. 188-197.
    98. Hayward, K.L., et al., Detecting non-alcoholic fatty liver disease and risk factors in health databases: Accuracy and limitations of the ICD-10-AM. BMJ Open Gastroenterol, 2021. 8(1).
    99. Hayward, K.L., et al., ICD-10-AM codes for cirrhosis and related complications: Key performance considerations for population and healthcare studies. BMJ Open Gastroenterol, 2020. 7(1).
    100. Chen, J.H., et al., Bariatric surgery did not increase the risk of gallstone disease in obese patients: A comprehensive cohort study. Obes Surg, 2019. 29(2): p. 464-473.
    101. Fan, C.M., et al., Shorter door-to-balloon time in st-elevation myocardial infarction saves insurance payments: A single hospital experience in Taiwan. Acta Cardiol Sin, 2015. 31(2): p. 127-35.
    102. Lee, W.A., et al., Risks of newly onset hemorrhagic stroke in patients with neovascular age-related macular degeneration. Pharmacoepidemiol Drug Saf, 2017. 26(10): p. 1277-1285.
    103. Sheu, M.J., et al., Validity of ICD-10-CM codes used to identify patients with chronic hepatitis b and c virus infection in administrative claims data from the taiwan national health insurance outpatient claims dataset. Clin Epidemiol, 2020. 12: p. 185-192.
    104. Chen, T.Y., et al., Bariatric surgery may provide better protection than uvulopalatopharyngoplasty against major adverse cardiovascular events in obese patients with obstructive sleep apnea. Surg Obes Relat Dis, 2021. 17(4): p. 780-791.
    105. Luther, E., et al., Incidence and clinical outcomes of hypothyroidism in patients undergoing spinal fusion. Cureus, 2021. 13(8): p. e17099.
    106. Schneeweiss, S., Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf, 2006. 15(5): p. 291-303.
    107. Li, L., et al., Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev, 2016. 17(6): p. 510-9.
    108. 台灣行政院性別平等會. 國人過重及肥胖盛行率. [cited 2022 06]; Available from: https://www.gender.ey.gov.tw/gecdb/Stat_Statistics_DetailData.aspx?sn=%24mQvpHYEayTTt8pmhMjRvA%40%40.
    109. 衛生福利部國民健康署. 國民營養健康狀況變調查成果報告2013-2016年、國民營養健康狀況變調查成果報告2017-2020年. [cited 2022 06]; Available from: https://www.hpa.gov.tw/Pages/List.aspx?nodeid=3998.
    110. University, D.o.B.a.V. Power and sample size. Build version: a57e8c3 (Feb 16, 2021). 2021 [cited 2022 08]; Available from: https://vbiostatps.app.vumc.org/ps/dichot.
    111. Miyazaki, M., et al., Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol Med Rep, 2012. 5(3): p. 729-33.
    112. Cui, J., et al., Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. J Hepatol, 2016. 65(2): p. 369-76.
    113. Smits, M.M., et al., Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. Diabetologia, 2016. 59(12): p. 2588-2593.
    114. Foley, J.E., et al., Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: A randomised controlled trial. Diabetologia, 2011. 54(8): p. 1985-91.
    115. Raccah, D., et al., Efficacy and safety of lixisenatide in elderly (≥65 years old) and very elderly (≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme. Diabetes Metab Res Rev, 2015. 31(2): p. 204-11.
    116. Bode, B.W., et al., Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies. Am J Geriatr Pharmacother, 2011. 9(6): p. 423-33.
    117. Kato, K., et al., The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: A randomized, crossover, controlled clinical trial. Expert Opin Pharmacother, 2017. 18(8): p. 743-751.
    118. 中華民國糖尿病協會. 第2型糖尿病臨床照護指引. 2022 [cited 2022 06]; Available from: http://www.endo-dm.org.tw/dia/direct/.
    119. Draznin, B., et al., 9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2022. Diabetes Care, 2022. 45(Suppl 1): p. S125-s143.
    120. Cusi, K., et al., American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract, 2022. 28(5): p. 528-562.
    121. Xia, L., et al., Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis. Diabetes Res Clin Pract, 2021. 177: p. 108904.
    122. 社團法人中華民國糖尿病衛教學會. 臺灣糖尿病年鑑2019第2型糖尿病. [cited 2022 07]; Available from: https://www.tade.org.tw/download/index.asp?Type=11.

    無法下載圖示 校內：2027-09-01公開
    校外：2027-09-01公開
    電子論文尚未授權公開，紙本請查館藏目錄
    QR CODE